Abstract
Generalized pustular psoriasis (GPP) is a rare, severe neutrophilic skin disease characterized by sudden widespread eruption of sterile pustules with or without systemic symptoms. GPP may be life threatening in cases with severe complications such as cardiovascular failure, acute respiratory distress syndrome, and serious infections. Impetigo herpetiformis (IH) is a GPP that is induced and exacerbated by pregnancy and occurs most frequently during the last trimester. IH may result in poor or fatal neonatal outcomes, including placental insufficiency, fetal abnormalities, stillbirth, and early neonatal death. Most patients have prompt remission in the postpartum period; however, earlier appearance and more severe symptoms are observed during subsequent pregnancies. Appropriate treatment and close monitoring of the mother and fetus are vital for the management of patients with IH. Particular attention is required for the management of patients with IH to avoid an influence on the fetus. However, data regarding treatments for GPP in pregnant women are sparse. Over the last decade, many patients with IH have been treated with cyclosporine, corticosteroids, tumor necrosis factor-α inhibitors, interleukin (IL)-17 and IL-12/23 inhibitors, and granulocyte and monocyte adsorption apheresis (GMA). GMA may be an important option for patients with IH as it is presently one of the safest available therapeutic options, but there have been no reports to fully confirm its safety in pregnant patients with GPP. Alternatively, based on recent advances in the understanding of the role of the IL-36 axis in the pathogenesis of GPP, biologic agents that target the IL-36 pathway may demonstrate promising efficacy in IH.
Similar content being viewed by others
References
Menter A, Van Voorhees AS, Hsu S. Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options. Dermatol Ther (Heidelb). 2021;11:1917–29.
Genovese G, Moltrasio C, Cassano N, Maronese CA, Vena GA, Marzano AV. Pustular psoriasis: from pathophysiology to treatment. Biomedicines. 2021;9:1746.
Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131–44.
Wang H, Jin H. Update on the aetiology and mechanisms of generalized pustular psoriasis. Eur J Dermatol. 2021;31:602–8.
Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233–40.
Dai Y-X, Chen C-C. Flare-up of pustular psoriasis after ustekinumab therapy: case report and literature review. Dermatol Sin. 2018;36:222–5.
Namazi N, Dadkhahfar S. Impetigo herpetiformis: review of pathogenesis, complication, and treatment. Dermatol Res Pract. 2018;2018:5801280.
Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J Womens Health. 2018;10:109–15.
Vena GA, Cassano N, Bellia G, Colombo D. Psoriasis in pregnancy: challenges and solutions. Psoriasis (Auckl). 2015;5:83–95.
Sugiura K, Takemoto A, Yamaguchi M, Takahashi H, Shoda Y, Mitsuma T, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Investig Dermatol. 2013;133(11):2514–21.
Kinoshita M, Ogawa Y, Takeichi T, Okamoto T, Osada A, Shimada S, et al. Impetigo herpetiformis with IL-36RN mutation successfully treated with secukinumab. Eur J Dermatol. 2018;28(3):381–2.
Ogrum A, Takci Z, Seckin HY, Cetin E. Treatment resistant impetigo herpetiformis treated with infliximab. Dermatol Ther. 2019;32(2): e12839.
Yamashita T, Hamada T, Maruta Y, Kajita A, Hirai Y, Morizane S, et al. An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare-up. Int J Dermatol. 2019;58(3):350–3.
Kondo RN, Araújo FM, Pereira AM, Lopes VC, Martins LM. Pustular psoriasis of pregnancy (impetigo herpetiformis)—case report. An Bras Dermatol. 2013;88(6 Suppl 1):186–9.
Iwasaki A, Kawakami H, Okubo Y. Granulocyte/monocyte adsorption apheresis as a novel therapeutic approach in the treatment of an impetigo herpetiformis case. Ther Apher Dial. 2018;22(4):414–6.
Chhabra G, Chanana C, Verma P, Saxena A. Impetigo herpetiformis responsive to secukinumab. Dermatol Ther. 2019;32(5): e13040.
Mohaghegh F, Galehdari H, Rezaie M. Pustular psoriasis of pregnancy in early first trimester: a case report. Clin Case Rep. 2021;9(7): e04438.
Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45:1235–70.
Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Köks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1792–9.
Halevy S, Kardaun SH, Davidovici B, Wechsler J. EuroSCAR and RegiSCAR study group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol. 2010;163:1245–52.
Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int J Mol Sci. 2016;17:1214.
Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, et al. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Investig Dermatol. 2013;133:1904–7.
Navarini AA, Simpson MA, Borradori L, Yawalkar N, Schlapbach C. Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis. JAMA Dermatol. 2015;151:452–3.
Rogel-Vence M, González-Ruiz L, Santiago Sánchez-Mateos JL. Annular pustular psoriasis. Med Clin. 2020;155:326.
Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143:1021–6.
Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981–3.
Choon SE, Lebwohl MG, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3): e043666.
Komine M, Morita A. Generalized pustular psoriasis: current management status and unmet medical needs in Japan. Expert Rev Clin Immunol. 2021;17(9):1015–27.
Ohnishi H, Kadowaki T, Mizutani Y, Nishida E, Tobita R, Abe N, et al. Genetic background and therapeutic response in generalized pustular psoriasis patients treated with granulocyte and monocyte adsorption apheresis. Eur J Dermatol. 2018;28:108–11.
Samotij D, Szczęch J, Reich A. Generalized pustular psoriasis: divergence of innate and adaptive immunity. Int J Mol Sci. 2021;22(16):9048.
Hussain S, Berki DM, Choon S-E, Burden AD, Allen MH, Arostegui JI, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135(4):1067-1070.e9.
Wang T-S, Chiu H-Y, Hong J-B, Chan C-C, Lin S-J, Tsai T-F. Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients. Arch Dermatol Res. 2016;308(1):55–63.
Liu ZJ, Tian YT, Shi BY, Zhou Y, Jia XS. Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis: a PRISMA-compliant systematic review and meta-analysis. Medicine. 2020;99: e23068.
Mössner R, Wilsmann-Theis D, Oji V, Gkogkolou P, Löhr S, Schulz P, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018;178:740–8.
Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–8.
Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89:432–7.
Yoshikawa M, Rokunohe D, Kimura A, Takahashi M, Korekawa A, Nakajima K, et al. Significance of IL36RN mutation analyses in the management of impetigo herpetiformis: a case report and review of published cases. J Dermatol. 2021;48:699–702.
Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Investig Dermatol. 2014;134(6):1755–7.
Fujii K, Takahashi T, Matsuyama K, Fujii A, Mizutani Y, Ohnishi H, et al. Impetigo herpetiformis with a CARD14 Thr79Ile variant successfully treated with granulocyte and monocyte adsorption apheresis. J Dermatol. 2020;47(3):e84–5.
Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization diseases: an emerging concept encompassing various inflammatory keratinization disorders of the skin. J Dermatol Sci. 2018;90:105–11.
Mahil SK, Twelves S, Farkas K, Setta-Kaffetzi N, Burden AD, Gach JE, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Investig Dermatol. 2016;136:2251–9.
Frey S, Sticht H, Wilsmann-Theis D, Gerschütz A, Wolf K, Löhr S, et al. Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis. J Investig Dermatol. 2020;140:1451–5.
Zhang Z, Ma Y, Zhang Z, Lin J, Chen G, Han L, et al. Identification of two loci associated with generalized pustular psoriasis. J Investig Dermatol. 2015;135:2132–4.
Vergnano M, Mockenhaupt M, Benzian-Olsson N, Paulmann M, Grys K, Mahil SK, et al. Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease. Am J Hum Genet. 2020;107:539–43.
Xiao H, Guo X, Hu B, Liu J, Zhao S, Xu Z, et al. Generalized pustular psoriasis in patients with interferon gamma (IFN-γ) receptor deficiency and mycobacterial infection. J Clin Immunol. 2021;41:829–33.
Murrieta-Coxca JM, Rodríguez-Martínez S, Cancino-Diaz ME, Markert UR, Favaro RR, Morales-Prieto DM. IL-36 cytokines: regulators of inflammatory responses and their emerging role in immunology of reproduction. Int J Mol Sci. 2019;20:1649.
Ainscough JS, Macleod T, McGonagle D, Brakefield R, Baron JM, Alase A, et al. Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ. Proc Natl Acad Sci USA. 2017;114:E2748–57.
Johnston A, Xing X, Wolterink L, Barnes DH, Yin Z, Reingold L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109–20.
Chang SE, Kim HH, Choi JH, Sung KJ, Moon KC, Koh JK. Impetigo herpetiformis followed by generalized pustular psoriasis: more evidence of same disease entity. Int J Dermatol. 2003;42:754–5.
Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, et al. Treatment of pustular psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:279–88.
Krueger J, Puig L, Thaçi D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51–64.
Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–19.
Luewan S, Sirichotiyakul S, Tongsong T. Recurrent impetigo herpetiformis successfully treated with methotrexate: a case report. J Obstet Gynaecol Res. 2011;37(6):661–3.
Jeon C, Nakamura M, Sekhon S, Yan D, Wu JJ, Liao W, et al. Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD Case Rep. 2017;3(6):495–7.
Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011–7.
Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355–62.
Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741–51.
Kromer C, Loewe E, Schaarschmidt ML, Pinter A, Gerdes S, Herr R, et al. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. 2021;34(2): e14814.
Ikeda S, Takahashi H, Suga Y, et al. Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis. J Am Acad Dermatol. 2013;68:609–17.
Shukuya R, Hasegawa T, Niwa Y, Okuma K, Ikeda S. Granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis. J Dermatol. 2011;38:1130–4.
Fujisawa T, Moriya C, Shibuya Y, Kanoh H, Seishima M. Combination therapy of infliximab and granulocyte/monocyte adsorption apheresis for refractory pustular psoriasis with psoriatic arthritis. Acta Derm Venereol. 2013;93:364–5.
Sugiura K, Haruna K, Suga Y, Akiyama M. Generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist successfully treated with granulocyte and monocyte adsorption apheresis. J Eur Acad Dermatol Venerol. 2014;28:1835–6.
Kanekura T, Hiraishi K, Kawahara K, Maruyama I, Kanzaki T. Granulocyte and monocyte adsorption apheresis (GCAP) for refractory skin diseases caused by activated neutrophils and psoriatic arthritis: evidence that GCAP removes Mac-1-expressing neutrophils. Ther Apher Dial. 2006;10:247–56.
Patsatsi A, Theodoridis TD, Vavilis D, Tzevelekis V, Kyriakou A, Kalabalikis D, et al. Cyclosporine in the management of impetigo herpetiformis: a case report and review of the literature. Case Rep Dermatol. 2013;5(1):99–104.
Luan L, Han S, Zhang Z, Liu X. Personal treatment experience for severe generalized pustular psoriasis of pregnancy: two case reports. Dermatol Ther. 2014;27(3):174–7.
Flynn A, Burke N, Byrne B, Gleeson N, Wynne B, Barnes L. Two case reports of generalized pustular psoriasis of pregnancy: Different outcomes. Obstet Med. 2016;9(2):55–9.
Iinuma S, Minami-Hori M, Honma M, Ishida-Yamamoto A. Acquired hemophilia A following generalized pustular psoriasis of pregnancy. J Dermatol. 2017;44(12):e324–5.
Yao X, Zhang X, Peng M, Wang H, Meng Y, Chen Y. A case of impetigo herpetiformis in which termination of pregnancy was required. J Int Med Res. 2020;48:300060520933811.
Ulubay M, Keskin U, Fidan U, Çiçek AF, Çalışkan E, Karaca RE, et al. Case report of a rare dermatosis in pregnancy: impetigo herpetiformis. J Obstet Gynaecol Res. 2015;41(2):301–3.
Wamalwa EW. Recurrent impetigo herpetiformis: case report. Pan Afr Med J. 2017;27:219.
Pitch M, Somers K, Scott G, Tausk F, Mercurio MG. A case of pustular psoriasis of pregnancy with positive maternal-fetal outcomes. Cutis. 2018;101(4):278–80.
Fiboumi AE, Chiheb S. Impetigo herpetiformis: a rare dermotosis of pregnancy. Pan Afr Med J. 2018;30:273.
Kanatani Y, Shinkuma S, Matsumoto Y, Mitsui Y, Shobatake C, Ogawa K, et al. Recurrence of impetigo herpetiformis carrying compound heterozygous mutations in IL36RN after remission with secukinumab. J Dermatol. 2021. https://doi.org/10.1111/1346-8138.16247.
Adachi A, Komine M, Hirano T, Tsuda H, Karakawa M, Murata S, et al. Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab. J Dermatol. 2016;43:1439–40.
Babuna Kobaner G, Polat EA. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: report of a challenging case. Dermatol Ther. 2020;33(4): e13571.
Beksac B, Adisen E, Gurer MA. Treatment of generalized pustular psoriasis of pregnancy with infliximab. Cutis. 2021;107(3):E2-5.
Fukushima H, Iwata Y, Arima M, Tanaka Y, Sugiura K. Efficacy and safety of treatment with anti-tumor necrosis factor-α drugs for severe impetigo herpetiformis. J Dermatol. 2021;48:207–10.
Mizutani Y, Mizutani YH, Matsuyama K, Kawamura M, Fujii A, Shu E, et al. Generalized pustular psoriasis in pregnancy, successfully treated with certolizumab pegol. J Dermatol. 2020;47(7):e262–3.
Saito-Sasaki N, Izu K, Sawada Y, Hino R, Nakano R, Shimajiri S, et al. Impetigo herpetiformis complicated with intrauterine growth restriction treated successfully with granulocyte and monocyte apheresis. Acta Derm Venereol. 2017;97(3):410–1.
Mizutani Y, Fujii K, Kawamura M, Inoue M, Mizutani YH, Matsuyama K, et al. Intensive granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis. J Dermatol. 2020;47(11):1326–9.
Liu N, Zhu L, Cheng Y, Yu N, Yi X, Ding Y. Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab: a case report. Acta Derm Venereol. 2020;100(15):adv00251.
Nakai Y, Ashida H, Kajita A, Yokoyama E, Sugiura K, Morizane S. Impetigo herpetiformis successfully treated with brodalumab. J Dermatol. 2021. https://doi.org/10.1111/1346-8138.16285.
Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11(10):1240.
Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 2016;30(3):488–90.
Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo R-M, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–33.
Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic Treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22(4):425–42.
Iznardo H, Puig L. Exploring the role of IL-36 cytokines as a new target in psoriatic disease. Int J Mol Sci. 2021;22(9):4344.
Viguier M, Guigue P, Pages C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010;153:66–7.
Huffmeier U, Watzold M, Mohr J, Schon MP, Mossner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170:202–4.
Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol. 2015;173(1):239–41.
Skendros P, Papagoras C, Lefaki I, Giatromanolaki A, Kotsianidis I, Speletas M, et al. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition. Br J Dermatol. 2017;176(1):212–5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were used to conduct this study or prepare this manuscript.
Conflicts of interest
Mariko Seishima, Kento Fujii, and Yoko Mizutani have no conflicts of interest that are directly relevant to the content of this article.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and materials
Not applicable.
Code availability
Not applicable.
Author contributions
MS wrote the first draft of the manuscript. All authors made significant contributions to the concept and planning and approved the final submitted version of the manuscript.
Rights and permissions
About this article
Cite this article
Seishima, M., Fujii, K. & Mizutani, Y. Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments. Am J Clin Dermatol 23, 661–671 (2022). https://doi.org/10.1007/s40257-022-00698-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-022-00698-9